4BASEBIO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,070 GBX | -4.46% |
|
+3.38% | +57.35% |
| Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
| Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Capitalization 1 | 75.75 | 87.45 | 137 | 137 |
| Enterprise Value (EV) 1 | 67.92 | 86.45 | 129.8 | 121.9 |
| P/E ratio | -23.7 x | -16.9 x | -17.8 x | -17.8 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 224 x | 326 x | 274 x | 68.5 x |
| EV / Revenue | 201 x | 323 x | 260 x | 61 x |
| EV / EBITDA | -21.2 x | -16 x | -17.8 x | -17.7 x |
| EV / FCF | -16 x | - | -15.5 x | -16 x |
| FCF Yield | -6.26% | - | -6.47% | -6.23% |
| Price to Book | 6.48 x | 12.3 x | -563 x | -17.4 x |
| Nbr of stocks (in thousands) | 12,317 | 12,317 | 12,805 | 12,805 |
| Reference price 2 | 6.150 | 7.100 | 10.70 | 10.70 |
| Announcement Date | 5/9/22 | 5/11/23 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | 0.462 | 0.338 | 0.268 | 0.5 | 2 |
| EBITDA 1 | -0.345 | -3.207 | -5.409 | -7.3 | -6.9 |
| EBIT 1 | -0.622 | -3.527 | -5.84 | -7.9 | -7.6 |
| Operating Margin | -134.63% | -1,043.49% | -2,179.1% | -1,580% | -380% |
| Earnings before Tax (EBT) 1 | -0.716 | -3.64 | -5.929 | -8.5 | -8.6 |
| Net income 1 | -0.719 | -3.235 | -5.15 | -7.7 | -7.7 |
| Net margin | -155.63% | -957.1% | -1,921.64% | -1,540% | -385% |
| EPS 2 | -0.0800 | -0.2600 | -0.4200 | -0.6000 | -0.6000 |
| Free Cash Flow 1 | -1.373 | -4.252 | - | -8.4 | -7.6 |
| FCF margin | -297.19% | -1,257.99% | - | -1,680% | -380% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 6/3/21 | 5/9/22 | 5/11/23 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 15 | 7.83 | 1 | 7.2 | 15.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -1.37 | -4.25 | - | -8.4 | -7.6 |
| ROE (net income / shareholders' equity) | -10.6% | -23.8% | -54.7% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | 1.720 | 0.9500 | 0.5800 | -0.0200 | -0.6200 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 0.35 | 1.51 | - | 1.7 | 1.2 |
| Capex / Sales | 75.97% | 447.34% | - | 340% | 60% |
| Announcement Date | 6/3/21 | 5/9/22 | 5/11/23 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +57.35% | 171M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 4BB Stock
- Financials 4basebio PLC
